 Outlook Therapeutics Inc NASDAQ:OTLK said the US Food and Drug Administration FDA has accepted its Biologics License Application BLA for its investigational ophthalmic formulation of bevacizumab for treating wet age-related macular degeneration wet AMD. The FDA set a Prescription Drug User Fee Act PDUFA goal date of 29 August 2023. 